The cash inflow associated with the sale of equity securities classified as available-for-sale securities.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585

Name:	us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Financial Instruments Financial Instruments (Details Textual 2) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Business Acquisition [Line Items]
Proceeds from sales of strategic investments	$ 476.0	$ 0.0
Strategic Investments
Business Acquisition [Line Items]
Strategic investment portfolio	394.5
Ionis Pharmaceuticals
Business Acquisition [Line Items]
Proceeds from sales of strategic investments	$ 382.0
Other noncurrent assets \| Strategic Investments
Business Acquisition [Line Items]
Strategic investment portfolio			$ 676.3